Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004585 · ClinicalTrials.gov registry record · Phase 4
A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults
A Phase 4 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT00004585 is a Phase 4 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 40 participants.
The verdict
NCT00004585, a Phase 4 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to see if a certain combination of anti-HIV drugs is safe and effective in HIV-infected patients. The drug combination includes a tablet containing lamivudine and zidovudine (called Combivir) plus abacavir plus efavirenz.
Interventions
- DRUG Efavirenz
- DRUG Lamivudine/Zidovudine
- DRUG Abacavir sulfate
- DRUG Abacavir sulfate, Lamivudine and Zidovudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1999-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004585
The ClinicalTrials.gov registry entry for NCT00004585 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Efavirenz is the first listed.
NCT00004585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004585 about?
NCT00004585 is a clinical study titled "A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults". The purpose of this study is to see if a certain combination of anti-HIV drugs is safe and effective in HIV-infected patients. The drug combination includes a tablet containing lamivudine and zidovudine (called Combivir) plus abacavir plus efavirenz.
What is the current status of trial NCT00004585?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 1999-10.
What interventions are being tested in trial NCT00004585?
The interventions under investigation include: Efavirenz (DRUG), Lamivudine/Zidovudine (DRUG), Abacavir sulfate (DRUG), Abacavir sulfate, Lamivudine and Zidovudine (DRUG).
Who is sponsoring clinical trial NCT00004585?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.